Diaverum today announced the appointment of Rafael Romanini as its new Chief Executive Officer, effective immediately. This follows the appointment of Dimitris Moulavasilis as Group CEO of M42, Diaverum’s strategic investor, which acquired the company in 2023. Mr. Moulavasilis will work closely with Mr. Romanini over the coming weeks to ensure a seamless transition.
Since joining Diaverum in 2018 as Country Manager for Brazil, Mr. Romanini has demonstrated outstanding leadership in driving operational excellence, expanding patient access, and fostering cross-regional collaboration. He was promoted to Regional Vice President in 2021, initially overseeing Iberia and LATAM, before his role expanded to include Central and Eastern Europe. In March 2024, he assumed responsibility for Diaverum’s operations across the whole of Europe and LATAM, further strengthening his expertise in managing complex, multinational healthcare businesses. Prior to joining Diaverum, Mr. Romanini held senior leadership positions at both publicly listed and start-up healthcare companies, leading strategic and business growth initiatives.
This appointment follows the transition of Dimitris Moulavasilis, Diaverum’s CEO since 2018, to the role of Group CEO of M42, Diaverum’s strategic investor, effective immediately. Mr. Moulavasilis brings over 30 years of international experience in healthcare services and medical technology to his new role as Group CEO of M42. Most recently, he's been serving as CEO of M42’s Global Patient Care platform; as CEO of Diaverum, he led major digital transformation initiatives and strengthened the company’s global presence. Prior to that, Mr. Moulavasilis was Group CEO of Affidea, a leading European provider of imaging, outpatient and cancer care services, where he successfully led the company’s growth and transformation between 2012 and 2018.
With Mr. Moulavasilis’ and Mr. Romanini’s combined deep healthcare sector knowledge and proven track record in operational excellence, innovation, and sustainable growth, Diaverum and M42 are well-positioned for continued success and impact.
Dimitris Moulavasilis, Group CEO of M42, commented: " Rafael’s inspiring leadership, deep understanding of the business, and unwavering commitment to care excellence, innovation, and sustainable growth make him the right person to lead Diaverum into its next chapter. His appointment ensures that the company remains firmly committed to its mission of delivering life-enhancing renal care, while also supporting national healthcare systems to manage the growing burden of chronic conditions. I am immensely proud of what we have achieved together at Diaverum over the past seven years and equally excited about the future under Rafael’s leadership."
Under Mr. Romanini’s stewardship, Diaverum will continue to advance its purpose-driven mission and values, delivering life-enhancing renal care to patients worldwide and expanding its footprint into new markets.
Rafael Romanini, Group CEO of Diaverum, said: "Diaverum’s journey has been one of sustainable growth and transformation, into a leading global renal care provider, distinguished by our unparalleled patient care, pioneering digital & AI capabilities, and strong brand identity. Since 2008, we have added 264 clinics, entered 14 new markets, more than quadrupled our patient base and, more importantly, consistently improved our Clinical Performance Measurement scores year-on-year, achieving an all-time high in 2024. I am committed to building on this legacy, accelerating both organic and inorganic growth, and expanding access to high-quality renal care for underserved communities – because everyone deserves a fulfilling life. Together with our teams around the world, we will continue to deliver meaningful outcomes for patients, communities, and health systems, while creating sustainable value for our strategic investor."